

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Sokawa, *et al.*

APPLICATION No.: 10/578,123

FILED: May 1, 2006

I.A. FILING DATE: October 27, 2004

FOR: METHOD OF TREATMENT USING INTERFERON-TAU

EXAMINER: To Be Assigned

ART UNIT: To Be Assigned

CONF. No: 5042

**Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the National Stage of an International Application or before the mailing date of a first Office Action on the merits or before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last (37 CFR 1.97(b)(4)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

B. Cited Information

- ☒ Copies of references 1-18 are issued patent(s) and published application(s) and are not included (see C.F.R. § 1.98(a)(2)(i)).
- ☒ Copies of references 19-88 can be found in corresponding U.S. application 10/719,472, filed November 21, 2003, of which this application claims priority under 35 U.S.C. §120, and are not being submitted (see C.F.R. § 1.98(d)).

C. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

D. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

E. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP

Date: 11.29.06

Judy M. Mohr
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/578,123
				Confirmation Number	5042
				Filing Date	May 1, 2006
				First Named Inventor	Sokawa, et al.
				Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned				
Sheet	1	of	5	Attorney Docket No.	55600-8013.US02

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	4,683,195		Mullis et al.	07/28/87	
	2.	4,683,202		Mullis	07/28/87	
	3.	4,766,068		Oeda et al.	08/23/88	
	4.	4,769,238		Rutter	09/06/88	
	5.	5,019,382		Cummins Jr.	05/28/91	
	6.	5,372,808		Blatt & Taylor	12/13/94	
	7.	5,438,040		Ekwuribe	08/01/95	
	8.	5,738,845		Imakawa	04/14/98	
	9.	5,882,640		Cummins	03/16/99	
	10.	5,906,816		Soos et al.	05/25/99	
	11.	5,910,304		Cummins	06/08/99	
	12.	5,958,402		Bazer et al.	09/28/99	
	13.	6,036,949		Richards & Sherwood	03/14/00	
	14.	6,060,450		Soos et al.	05/09/00	
	15.	6,191,105		Ekwuribe et al.	02/20/01	
	16.	6,346,243		Brod	02/12/02	
	17.	6,372,206		Soos et al.	04/16/02	
	18.	7,105,154	B2	Sokawa et al.	09/12/06	

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	19.	PCT	WO 90/09806		Bazer & Johnson	09/07/90		
	20.	PCT	WO 94/10313		Bazer et al.	05/11/94		
	21.	PCT	WO 00/78266		Pontzer et al.	12/28/00		
	22.	PCT	WO 96/28183		Soos et al.	09/19/96		
	23.	PCT	WO 96/35789		Bazer et al.	11/14/96		
	24.	PCT	WO 02/006343		Pegen Corporation	01/24/02		
	25.	PCT	WO 03/061720		Soulie-Ziakovic et al.	07/31/03		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/578,123
				Confirmation Number	5042
				Filing Date	May 1, 2006
				First Named Inventor	Sokawa, et al.
				Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned				
Sheet	2	of	5	Attorney Docket No.	55600-8013.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	26.	Adah, S.A., et al., <i>Current Medicinal Chemistry</i> <u>8</u> :1189-1212, (2001).	
	27.	Alexenko, A.P., et al., <i>Journal of Interferon and Cytokine Research</i> <u>17</u> :769-779, (1997).	
	28.	Amidon, G.L., et al., <i>Peptide and Protein Drug Delivery, Alfred Benzon Symposium</i> <u>43</u> :146-152, (1998).	
	29.	Bayley, D., et al., <i>J Pharm Pharmacol</i> <u>47</u> :721-724, (1995).	
	30.	Bernkop-Schnürch, A. and Gilge, B., <i>Drug Development and Industrial Pharmacy</i> <u>26</u> (2):107-113, (2000).	
	31.	Bocci, V., <i>Journal of Biological Regulators and Homeostatic Agents</i> <u>4</u> (2):81-83, (1990).	
	32.	Bocci, V., <i>Journal of Interferon and Cytokine Research</i> <u>19</u> :859-861, (1999).	
	33.	Bartol, F.F., et al., <i>Biology of Reproduction</i> <u>33</u> :745-759 abstract only (1985).	
	34.	Bazer, F.W. and Johnson, H.M., <i>AJRI</i> <u>26</u> :19-22 (1991).	
	35.	Brod, S.A., et al., <i>Neurology</i> <u>44</u> :1144-1148, (1994).	
	36.	Brod, S.A., et al., <i>Journal of Interferon and Cytokine Research</i> <u>15</u> :115-122, (1995).	
	37.	Brod, S.A., <i>Arch Neurol</i> <u>54</u> :1300-1302, (1997).	
	38.	Brod, S.A., et al., <i>Diabetologia</i> <u>41</u> :1227-1232, (1998).	
	39.	Brod, S.A., <i>Journal of Interferon and Cytokine Research</i> <u>19</u> :841-852, (1999).	
	40.	Castelli, J., et al., <i>Biomed & Pharmacother</i> <u>52</u> :386-390, (1998).	
	41.	Choo, Q.-L., et al., <i>Science</i> <u>244</u> :359-362 (1989).	
	42.	Choo, Q.-L., et al., <i>Proc. Natl. Acad. Sci. USA</i> , <u>88</u> :2451-2455 (1991).	
	43.	Clayette, P., et al., <i>Pathologie Biologie</i> , <u>47</u> (4):553-559 (1999).	
	44.	Cotler, S.J., et al., <i>Journal of Viral Hepatitis</i> <u>7</u> :211-217 (2000).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/578,123
				Confirmation Number	5042
				Filing Date	May 1, 2006
				First Named Inventor	Sokawa, et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	3	of	5	Attorney Docket No.	55600-8013.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	45.	Cross, J.C., et al., <i>Proc. Natl. Acad. Sci. USA</i> <u>88</u> :3817-3821 (1991).	
	46.	Dianzani, F., <i>Journal of Interferon Research</i> pps. 109-118, (1992).	
	47.	Dieperink, E., et al., <i>Am. J. Psychiatry</i> <u>157</u> :867-876 (2000).	
	48.	Ecker, D.J., et al., <i>Journal of Biological Chemistry</i> <u>264</u> (13):7715-7719 (1989).	
	49.	Eiamtrakarn, S., et al., <i>Biomaterials</i> <u>23</u> :145-152, (2002).	
	50.	Gnatek, G.G., et al., <i>Biology of Reproduction</i> <u>41</u> :655-663 (1989).	
	51.	Helmer, S.D., et al., <i>J. Reprod. Fert.</i> , <u>79</u> :83-91 (1987).	
	52.	Imakawa, K., et al., <i>Nature</i> , <u>330</u> :377-379 (1987).	
	53.	Imakawa, K., et al., <i>Molecular Endocrinology</i> , <u>3</u> :127-139 (1989).	
	54.	Jacobs, B.L., et al., <i>Virology</i> <u>219</u> :339-349, (1996).	
	55.	Jarpe, M.A., et al., <i>Protein Engineering</i> <u>7</u> (7):863-867 (1994).	
	56.	Jiménez-Sáenz, M., et al., <i>Journal of Gastroenterology and Hepatology</i> <u>15</u> :567-569 (2000).	
	57.	Johnson, H.M.47, et al., <i>Scientific American</i> <u>270</u> (5):40-47, (1994).	
	58.	Le Page, C., et al., <i>Rev Immunogenetics</i> <u>2</u> :374-386, (2000).	
	59.	Milstein, S.J., et al., <i>Journal of Controlled Release</i> <u>53</u> :259-267, (1998).	
	60.	Lawson, C.M. and Beilharz, M.W., <i>Journal of Interferon and Cytokine Research</i> <u>19</u> :863-867, (1999).	
	61.	Magrin, S., et al., <i>Hepatology</i> <u>19</u> :273-279 (1994).	
	62.	Nakajima, A. and Sokawa, Y., <i>Journal of Interferon and Cytokine Research</i> <u>22</u> :397-402, (2002).	
	63.	Ott, T.L., et al., <i>Journal of Interferon Research</i> <u>11</u> :357-364 (1991).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/578,123
				Confirmation Number	5042
				Filing Date	May 1, 2006
				First Named Inventor	Sokawa, et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	4	of	5	Attorney Docket No.	55600-8013.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	64.	Pawlotsky, J.-M., et al., <i>Journal of Interferon and Cytokine Research</i> <u>15</u> :857-862 (1995).	
	65.	Pontzer, C.H., et al., <i>Biochem Biophys Res Communications</i> <u>152</u> (2):801-807, (1988).	
	66.	Pontzer, C.H., et al., <i>Pro Natl Acad Sci USA</i> <u>87</u> :5945-5949, (1990).	
	67.	Reddy, S.M., et al., <i>Drugs of Today</i> <u>35</u> (7):537-580, (1999).	
	68.	Roberts, R.M., et al., <i>Endocrine Review</i> <u>13</u> (3):432-452 (1992).	
	69.	Roberts, R.M., et al., <i>J Interferon Cytokine Res</i> <u>18</u> :805, (1998).	
	70.	Saez-Royuela, F., et al., <i>Hepatology</i> <u>10</u> (4):646 (1989).	
	71.	Saito, H., et al., <i>Journal of Viral Hepatitis</i> <u>7</u> :64-74 (2000).	
	72.	Samuel, C.E., <i>Hokkaido J Med Sci</i> <u>69</u> (6):1339-1347, (1994).	
	73.	Samuel, C.E., <i>Clinical Microbiology Reviews</i> <u>14</u> (4):778-809, (2001).	
	74.	Satoh, Y.I., et al., <i>J Interferon Cytokine Res</i> <u>19</u> :887-894, (1999).	
	75.	Schröder, H.C., et al., <i>Int J Biochem</i> <u>24</u> (1):55-63, (1992).	
	76.	Shindo, M., et al., <i>Hepatology</i> <u>9</u> (5):715-719, (1989).	
	77.	Short, Jr., E.C., et al., <i>Biology of Reproduction</i> <u>44</u> :261-268, (1991).	
	78.	Singh, B.N., <i>Clin Pharmacokinet</i> <u>37</u> (3):213-255, (1999).	
	79.	Sood, A. and Panchagnula, R., <i>Chem Rev</i> <u>101</u> :3275-3303, (2001).	
	80.	Soos, J.M., et al., <i>Journal of Neuroimmunology</i> <u>75</u> :43-50, (1997).	
	81.	Stoll, B.R., et al., <i>Journal of Controlled Release</i> <u>64</u> :217-228, (2000).	
	82.	Takayama, S., et al., <i>J Interferon Cytokine Res</i> <u>19</u> :895-900, (1999).	
	83.	Thorbecke, G.J., et al., <i>Arthritis & Rheumatism</i> <u>42</u> (1):110-118, (1999).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

